PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

The Era of Pharma and Biotech Outsourcing is Here to Stay

Over the past ten years, more and more pharma and biotech companies have turned to CROs, CMOs and CDMOs to assist in the preformulation, development and manufacturing of their latest innovations. Outsourcing is now a multi-billion dollar industry. Most spending is focused on early development, with around two-thirds of annual spending being outsourced. This report, commissioned by Biopharma Group, discusses why so many pharma and biotech companies have transitioned from doing their R&D in-house to outsourcing it.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/12/The-era-of-pharma-and-biotech.pdf” width=”100%” height=”900px” style=”border:0;”]

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40